Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies
about
Potential prognostic, diagnostic and therapeutic markers for human gastric cancerMolecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and TreatmentPromoter Hypermethylation of FANCF and Susceptibility and Prognosis of Epithelial Ovarian CancerAdenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials.Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.The NF1 somatic mutational landscape in sporadic human cancers.Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary.Expression profile of COL2A1 and the pseudogene SLC6A10P predicts tumor recurrence in high-grade serous ovarian cancer.JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancerNext-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations.Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma.Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.Clinical insights from metagenomic analysis of sputum samples from patients with cystic fibrosis.Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissueOncogenes associated with drug resistance in ovarian cancer.Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patientsDownregulation of lncRNA TUBA4B is Associated with Poor Prognosis for Epithelial Ovarian Cancer.Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancerGenomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women.Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.A comprehensive genomic meta-analysis identifies confirmatory role of OBSCN gene in breast tumorigenesis.Sequencing of Lynch syndrome tumors reveals the importance of epigenetic alterations.Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma.Molecular Genetic Analysis of Ovarian Brenner Tumors and Associated Mucinous Epithelial Neoplasms: High Variant Concordance and Identification of Mutually Exclusive RAS Driver Mutations and MYC Amplification.Tumor evolution and chemoresistance in ovarian cancer
P2860
Q26866200-808BB72A-9EE9-40CB-9E53-9B94D4E9945EQ28066904-E725C858-D3E4-44B4-9391-87C72D5B7D3CQ28269159-46A98437-E20B-480B-B18B-064E04F2CD7CQ30301145-484A2FEF-77F2-4972-99CB-E560CB5C86BFQ33415400-F92333B4-394D-4BE2-BC11-F11DD9219530Q33823452-ED0B62CE-4DBC-47F7-A0B8-E6BD7BA4D959Q34181172-8B0C8586-E27A-4C54-A931-C04D38D80F6AQ34491120-FD92141B-B6DB-4C35-9BEC-5E25230FF224Q35740107-4DA91A59-7F42-43FA-B79C-0393F39338F1Q36369910-2CF48667-EDC7-482E-853A-215E89BB3361Q36979335-09B6BB72-4821-416D-8546-1E2A877BC657Q37223322-0D530266-7576-4D1D-97EF-F5206211D188Q37546291-CC046B21-C131-440C-99BA-D7358727DB58Q37565541-DD1FF8ED-7C1D-4D09-918C-4854668D3742Q37688565-40ED5077-00A6-4F49-BDB2-82C90F3E9F73Q38226577-6D65B1E6-D1B7-4FCC-AB23-B7410FAD7B53Q38374414-69FA73DA-B90C-4326-BBAB-F279D02236CDQ38746342-9F5F90B9-8013-4B78-B710-11F1BD49DA62Q38848614-366831F0-CFE4-47AF-8C6C-D0B9FCE5B32FQ41015074-8FD64B45-B7F1-4C89-BEC5-923E60307A59Q41519401-62999484-1E4B-4444-8BC1-A98B19974E08Q46879650-1FDC1C45-FED7-4A6D-8A43-ED228EFCE95AQ47142351-B43263B3-82FD-4F8C-8C4D-D08EB4DE6822Q47156477-0C429D38-E651-4D12-9AA8-A388721237E1Q47882632-700CEA90-226B-4F0E-BA3A-BDD0B281E80CQ55135308-30398BFB-4FDF-4A33-ACEA-0B169ADD6E89Q58733743-09A2349A-DC75-4A05-ABBE-5A52E6AB9930
P2860
Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Comprehensive genomic profilin ...... w routes to targeted therapies
@ast
Comprehensive genomic profilin ...... w routes to targeted therapies
@en
Comprehensive genomic profilin ...... w routes to targeted therapies
@nl
type
label
Comprehensive genomic profilin ...... w routes to targeted therapies
@ast
Comprehensive genomic profilin ...... w routes to targeted therapies
@en
Comprehensive genomic profilin ...... w routes to targeted therapies
@nl
prefLabel
Comprehensive genomic profilin ...... w routes to targeted therapies
@ast
Comprehensive genomic profilin ...... w routes to targeted therapies
@en
Comprehensive genomic profilin ...... w routes to targeted therapies
@nl
P2093
P3181
P1433
P1476
Comprehensive genomic profilin ...... w routes to targeted therapies
@en
P2093
D Zajchowski
L K Shawver
P J Stephens
R Yelensky
V A Miller
P3181
P356
10.1016/J.YGYNO.2013.06.019
P407
P577
2013-09-01T00:00:00Z